A patient with type 2 diabetes and diabetic dyslipidemia is started on saroglitazar. Which of the following is a potential adverse effect associated with saroglitazar/PPAR agonist therapy?
- A. Severe neutropenia
- B. Weight gain and peripheral edema
- C. Ototoxicity
- D. Gingival hyperplasia
0
voters
MBH/PS